Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 2,989 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 2,989 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.93, for a total transaction of $14,735.77. Following the sale, the chief executive officer owned 182,161 shares in the company, valued at approximately $898,053.73. The trade was a 1.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Trading Down 1.8%

NASDAQ CVKD traded down $0.09 on Friday, reaching $4.91. 28,017 shares of the stock were exchanged, compared to its average volume of 54,242. Cadrenal Therapeutics, Inc. has a one year low of $4.21 and a one year high of $15.99. The firm has a market capitalization of $14.09 million, a PE ratio of -0.87 and a beta of 1.81. The company’s 50-day simple moving average is $5.35 and its two-hundred day simple moving average is $7.20.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.47. Sell-side analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cadrenal Therapeutics

Several large investors have recently bought and sold shares of the business. DRW Securities LLC bought a new stake in Cadrenal Therapeutics in the fourth quarter worth $171,000. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics in the third quarter worth $274,000. Geode Capital Management LLC increased its position in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics in the third quarter worth $103,000. Institutional investors own 7.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CVKD shares. Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reduced their price objective on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.